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mAbstract
Background: Mechanical stress induced by injurious ventilation leads to
pro-inflammatory cytokine production and lung injury. The extracellular-signal-
regulated-kinase, ERK1/2, participates in the signaling pathways activated upon
mechanical stress in the lungs to promote the inflammatory response. Tumor
progression locus 2 (Tpl2) is a MAP3kinase that activates ERK1/2 upon cytokine or
TLR signaling, to induce pro-inflammatory cytokine production. The role of Tpl2 in
lung inflammation, and specifically in the one caused by mechanical stress has not
been investigated. The aim of the study was to examine if genetic or pharmacologic
inhibition of Tpl2 could ameliorate ventilator-induced lung injury.
Methods: Adult male wild-type and Tpl2-deficient mice were ventilated with normal or
high tidal volume for 4 h. Additional wild-type mice were treated with a Tpl2 inhibitor
either before or 30 min after initiation of high tidal ventilation. Non-ventilated mice of
both genotypes served as controls. The development of lung injury was evaluated by
measuring lung mechanics, arterial blood gases, concentrations of proteins, IL-6, and
MIP-2 in bronchoalveolar lavage fluid (BALF) and by lung histology. Data were compared
by Kruskal-Wallis non-parametric test and significance was defined as p < 0.05.
Results: Mechanical ventilation with normal tidal volume induced a mild increase of IL-6
in BALF in both strains. High tidal volume ventilation induced lung injury in wild-type
mice, characterized by decreased lung compliance, increased concentrations of proteins,
IL-6 and MIP-2 in BALF, and inflammatory cell infiltration on histology. All indices of lung
injury were ameliorated in Tpl2-deficient mice. Wild-type mice treated with the Tpl2
inhibitor, either prior of after the initiation of high tidal volume ventilation were protected
from the development of lung injury, as indicated by preserved lung compliance and
lower BALF concentrations of proteins and IL-6, than similarly ventilated, untreated
wild-type mice.
Conclusions: Genetic and pharmacologic inhibition of Tpl2 is protective in a mouse
model of ventilator-induced lung injury, ameliorating both high-permeability pulmonary
edema and lung inflammation.
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Lung injury; Mechanical stress; Mechanical ventilation2014 Kaniaris et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly credited.
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Ventilator-induced lung injury (VILI) is a well-recognized complication of mechanical
ventilation. The mechanical stress caused by a relatively high tidal volume, applied on
an injured lung causes an abnormally high distortion (strain) of lung cells. The cellular
responses to increased stress and strain result in alveolar barrier disruption and activation
of inflammation, therefore inducing or exacerbating acute lung injury (ALI).
Several cell types mediate the effects of strain induced by mechanical ventilation.
Increased strain, either in vivo or in vitro, impairs barrier properties of alveolar epithelial
and endothelial cells [1-3]. Moreover, both alveolar epithelial and endothelial cells have
been shown to produce pro-inflammatory cytokines when subjected to deformation [4,5].
Alveolar macrophages are also activated by cyclic stretch [6], and have been shown to
mediate not only inflammation, but also barrier dysfunction [6-8].
The extracellular signal-regulated kinase 1/2 (ERK1/2) is a member of the mitogen-
activated serine/threonine kinase (MAPK) family, which also includes the kinases p38
and C-Jun N-terminal Kinase (JNK). MAPK are highly conserved enzymes regulating a
vast array of cellular functions, including cell survival, proliferation, and differentiation,
as well as inflammation and stress responses [9,10]. Several cells respond to mechanical
forces by activating MAPK pathways [11]. Mechanical stress has been shown to stimulate
ERK1/2 in pulmonary epithelial cells [12] and endothelial cells [13]. ERK1/2 activation
upon cyclic stretch has been reported in human bronchial epithelial cells [4] and primary
rat alveolar epithelial cells [14]. In an in vitro model of VILI, cyclic stretch-induced
interleukin-8 production from lung epithelial cells was reduced by ERK1/2 inhibition [4].
In vivo, bleomycin plus ventilation-induced lung fibrosis was attenuated in mice with
pharmacologic inhibition of ERK1/2 [15].
Given the important role of ERK1/2 in cell proliferation, ERK1/2 inhibitors have been
investigated as candidate targets in cancer and rheumatoid arthritis [16-18]. Nevertheless,
defective ERK1/2 signaling has been associated with autoimmunity [19] raising concerns
for the use of ERK1/2 inhibition in inflammatory diseases, emphasizing the need for more
selective therapeutic targets [18].
Activation of each of the three MAPKs is controlled by several MAP3Ks ensuring the
specificity of signaling responses. Tumor progression locus 2 (Tpl2) is a MAP3kinase
that phosphorylates and activates the extracellular signal-regulated kinase (ERK1/2)
[20-22]. Tpl2 was originally identified as a proto-oncogene, but is now recognized to
play an important role in regulating ERK1/2 signaling in multiple cell types, including
T-cells, macrophages, and epithelial cells [22-26]. In vitro studies using Tpl2 overex-
pressing cells have shown that Tpl2 activates ERK, JNK, p38, and the transcription
factors NFAT (nuclear factor of activated T cells) and NF-κB [23,27]. In vivo, expression
of a constitutively active form of Tpl2 under the control of a T cell-specific promoter in
mice resulted in development of thymic lymphomas [21]. On the contrary, Tpl2-
deficent (Tpl2−/−) mice remain healthy throughout their normal life span [28]. Studies
on Tpl2−/−mice have proven that Tpl2 participates in signal transduction of TLR, T-cell
receptors, G protein-coupled receptors, tumor necrosis factor (TNF), and CD-40
[25,28-30]. In these studies, the anti-inflammatory effects of Tpl2 ablation were recog-
nized. Tpl2−/−macrophages produce less inflammatory mediators upon lipopolysachar-
ite (LPS) stimulation [29], and Tpl2−/−mice are resistant to LPS-induced shock [28]. In
a model of acute pancreatitis, lung inflammation was less in Tpl2−/−mice [31], and in a
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less bowel inflammation [32].
The present study examined the hypothesis that genetic and pharmacologic inhibition
of Tpl2 can ameliorate VILI. We first compared naïve wild type (WT) and Tpl2−/−mice,
as well as WT and Tpl2−/−mice ventilated for 4 h with normal tidal volume (VT), to
exclude any unexpected effect of Tpl2 deficiency on lung mechanics, response to
anesthesia, or normal-VT ventilation. We then subjected WT and Tpl2−/−mice to mechan-
ical ventilation with high VT, under conditions previously shown to induce severe VILI in
WT mice [33]. Finally, we examined the effect of pharmacologic inhibition of Tpl2 in WT
mice subjected to mechanical ventilation with high VT, when given as a pretreatment,
before the initiation of high VT, and, in a more clinically relevant approach, given after ini-
tiation of high VT ventilation.Methods
Animal experiments
We studied 12 groups of mice, a total of 58 male C57BL6 (WT) and 44 Tpl2−/−mice on
C57Bl6 background [28] at 8 to 10 weeks of age (25- to 30-g weight). The experimental
groups and number of mice in each group are presented in Table 1, and the experimental
procedure is shown in Figure 1. Mice were obtained from the Foundation of Research and
Technology Institute Animal Facility. All experiments were approved by the Research
Animal Care Committee of University of Crete Medical School and Heraklion Prefecture
Veterinary Authority. All experiments were performed at the experimental Intensive Care
Medicine laboratory at the Medical School of the University of Crete.
The effects of mechanical ventilation on the development of lung injury were studied
in WT and Tpl2−/−mice ventilated with either normal or high tidal volume (VT), as de-
tailed below, and described previously [33]. Mice were anesthetized with intraperitoneal
(i.p.) injection of ketamine 100 mcg/g and fentanyl 0.12 mcg/g [33], tracheostomized,
and ventilated using SAP830 ventilator (IITC Life Science, Woodland Hills, CA, USA).
Ventilation settings for normal VT were VT = 10 ml/kg resulting in peak inspiratory
pressure (PIP) = 9 ± 0.5 cmH2O, positive end-expiratory pressure PEEP =1.5 cmH2O,
respiratory rate (RR) =130 breaths/min, with recruitment maneuvers performed every
30 min. For high VT, ventilation settings were changed from normal VT after 30 minTable 1 Experimental groups
Strain treatment Sample (N)
WT Tpl2−/−
Control-PV curve and sample collection 10 10
Normal VT ventilation 8 8
High VT ventilation 8 8
High VT ventilation + Tpl2 inhibitor pretreatment 5
High VT ventilation + Tpl2 inhibitor posttreatment 5
Control-no ventilation (ERK1/2 phosphorylation) 6 6
Normal VT 60 min (ERK1/2 phosphorylation) 4 4
Normal VT 30 min + High VT 30 min (ERK1/2 phosphorylation) 8 8
Normal VT 30 min + High VT 30 min (ERK1/2 phosphorylation) + Tpl2 inhibitor pretreatment 4
Figure 1 Experimental procedure. At time 0, animals were anesthetized, tracheostomized, and connected
to the ventilator. Through the carotid artery, fluid and anesthesia were administered at a rate of 40 ml/kg/h
for 30 min after the initiation of ventilation. At 30 min, fluid infusion rate changed to 15 ml/kg/h in all
groups, and ventilator settings were changed as indicated in groups allocated to high VT ventilation. The
Tpl2 inhibitor-treated groups received an intraperitoneal injection of Tpl2 inhibitor (thick black arrow), either
5 min prior to the initiation of high VT ventilation (pretreatment) or 30 min after high VT ventilation (posttreatment).
Kaniaris et al. Intensive Care Medicine Experimental 2014, 2:15 Page 4 of 16
http://www.icm-experimental.com/content/2/1/15of hemodynamic stabilization, to high VT = 47 ± 2 ml/kg, targeted to a PIP = 35 ± 0.5
cmH2O, RR = 60 breaths/min, PEEP = 1.5 cmH2O, without recruitment maneuvers.
Fraction of inspired oxygen (FiO2) was 30% in all experiments, and inhaled carbon
dioxide (CO2) was added in high VT groups to prevent hypocapnia. Arterial blood
pressure, PIP, PEEP, and VT were monitored throughout the study. At the end of the
240-min experiment, blood was collected from the arterial line for blood gas analysis,
followed by inspiratory pressure volume curve, bronchoalveolar lavage fluid (BALF)
and tissue collection. For histological evaluation, lungs from mice not subjected to
BALF collection were inflated with 4% paraformaldehyde at a transpulmonary pressure
of 25 cmH2O.
The possible protective effects of pharmacologic Tpl2 inhibition were studied in WT
mice ventilated with high VT as described above, and treated with a Tpl2 inhibitor
(Calbiochem #616404, USA) 10 mg/kg, 20-μl DMSO in a 0.2-ml normal saline given as
a single i.p. injection as per manufacturer's instructions, and previous reports [34]. Two
groups of WT mice treated with Tpl2 inhibitor were studied: the pretreatment group,
in which the inhibitor was given 5 min prior to the initiation of high VT ventilation,
and the posttreatment group, in which the inhibitor was given 30 min after high VT
ventilation.
As controls served WT and Tpl2−/−mice ventilated briefly (approximately 1 min),
until paralyzed, to obtain an inspiratory pressure volume curve and subsequently BALF
and tissue samples.
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even after very brief periods of ventilation [14,15] was studied in WT and Tpl2−/−mice in
the same study groups, but total ventilation time was limited to 60 min. Due to the rapid
activation of ERK1/2 upon mechanical ventilation different controls were required for this
experiment. Specifically, as controls served mice of both genotypes not subjected to
mechanical ventilation, euthanized with pentobarbital. In these experiments, only BALF
cells and lungs were collected.Evaluation of lung injury
Ventilator-induced lung injury is characterized by high-permeability pulmonary edema
and inflammation. The presence of high-permeability pulmonary edema was evaluated
using lung compliance, oxygenation, and BALF protein concentration. The presence of
inflammation was evaluated by BALF cytokines. Lung histological evaluation also
provided information on alveolar membrane integrity and presence of inflammatory
cellular infiltration. As an indicator of lung compliance, we used the inspiratory
capacity, defined as the volume to inflate the lungs to an airway pressure of 25 cmH2O
[33]. Results are expressed as percentage (%) of control and normalized to body weight
due to the differences in weight of study mice. Concentration of proteins in BALF was
measured using bicinchoninic acid assay (Pierce Chemical Co, Rockford, IL, USA). The
levels of the proinflammatory cytokines, interleukin-6 (IL-6), and macrophage inflamma-
tory protein 2 (MIP-2), were measured in BALF ELISAs (R&D Systems Inc, Minneapolis,
MN, USA). Paraffin-embedded lung sections, sectioned 6-μm thick and stained with
hematoxylin and eosin, were analyzed by a pathologist blinded to the treatment groups. In
each group, 20 random high power fields (×400) were scored, for five independent
variables: neutrophils in alveolar spaces, neutrophils in interstitial spaces, hyaline mem-
branes, proteinaceous debris filling the airspaces, and alveolar septal thickening, as previ-
ously described [35]. The resulting injury score is a continuous value between 0 and 1.Evaluation of ERK1/2 phosphorylation in WT and TPL2−/−mice after high VT ventilation
Levels of ERK1/2 phosphorylation were evaluated in BALF cells by flow cytometry and
in lung homogenates by Western blot. BALF cells were immediately fixed in 1.5%
formaldehyde permeabilized by ice-cold methanol for 10 min and then washed and re-
suspended in PBS (Ca2+- and Mg2+-free) containing 0.1 mM EDTA, 5% FBS, and 0.05%
NaN3. BALF cells were first incubated with rabbit anti-mouse phospho-p44/42 MAPK
(ERK1/2) (Thr202/Tyr204) antibody (Cell Signaling Techn, Danvers, MA, USA) for 1 h
at 4°C. Then, cells were incubated for 20 min at 4°C with FITC goat anti-rabbit IgG
(BD Biosciences, Franklin Lakes, NJ, USA). To discriminate alveolar macrophages, cell
surface staining was carried out by incubation with PerCP-Cy5.5 anti-mouse CD11c
(Biolegent, San Diego, CA, USA) for 30 min at 4°C. Appropriate isotype control was
also used. The flow cytometry events were acquired in a MoFlo Legacy Cell Sorter
(Beckman Coulter, Inc., Fullerton, CA, USA) and analyzed with the use of Summit
Software (Summit Software, Inc., Fort Wayne, IN, USA). For Western blot analysis, a
100-μl tissue sample was suspended in 500 μl of lysis buffer containing 50 mM Tris
(pH 6.8), 2% sodium dodecyl sulfate, 5 mM EDTA, and protease inhibitors (Complete,
Boehringer, Ingelheim, Germany), homogenized, ultrasonicated, and centrifuged. Α 0.1*
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mercaptoethanol, and 50% [v/v] lysis buffer) was added. Samples were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes. Membranes were labeled with a phospho- and total ERK1/2 primary antibody
(Cell Signaling Technology, Danvers, MA, USA). Washed membranes were incubated with
goat anti-rabbit anti-serum conjugated with horseradish peroxidase (Amersham Inter-
national, Amersham, UK). Antigen-antibody complexes on the membranes were detected
by enhanced chemiluminescence (Amersham).Statistical analysis
Data were compared by one-way ANOVA, using the Shapiro-Wilk normality test, and
the Kruskal-Wallis test for non-parametric data with Dunn's multiple comparisons
posttest, with SigmaStat software. For each of the parameter evaluated, the comparisons
made included: comparison between similarly ventilated animals of different genotype or
treatment, and of ventilated animals with their genotype-matched controls. All data in
text are expressed as means ± SD. Significance was defined as p < 0.05.Results
Anesthesia and mechanical ventilation for 240 min were tolerated by WT and TPL2−/−mice
Blood pressure averaged 92 ± 20 mmHg after 30 min of MV and 93 ± 23 mmHg at the
end of the experiment in WT mice, and 98 ± 21 and 105 ± 24 mmHg, respectively, in
Tpl2−/−mice (p > 0.05 for all comparisons). All mice survived the 240 min of mechan-
ical ventilation.WT and TPL2−/−mice do not differ at baseline and after mechanical ventilation with normal VT
Control WT and Tpl2−/−mice had no differences on histological appearance, lung
compliance, and concentrations of proteins, IL-6 and MIP-2 in BALF. Similarly, after
240 min of mechanical ventilation with normal VT, WT, and Tpl2−/−, the mice had
no differences in all indices of lung injury studied, inspiratory capacity (Figure 2),
arterial oxygen (Figure 3), and concentration of proteins (Figure 4) and IL-6 (Figure 5)
in BALF. Mechanical ventilation with normal VT resulted in a similar increase in
BALF IL-6 concentration in both strains.Genetic deficiency of Tpl2−/−protects from high VT ventilation-induced lung injury
Mechanical ventilation with high VT-induced high-permeability pulmonary edema that
was more severe in WT than in Tpl2−/−mice. After 210 min of high VT ventilation,
lung compliance decreased in WT mice to 60% of control, but not in Tpl2−/−mice (93%
of control; Figure 2). The development of pulmonary edema was associated with im-
paired oxygenation (Figure 3). Tpl2−/−mice subjected to high VT ventilation had higher
PaO2 than WT mice (145 ± 18 vs. 70 ± 13 mmHg, p < 0.05, Figure 2). There were no
differences in PaCO2, pH, and lactate between the two genotypes after high VT ventila-
tion (data not shown). The concentration of proteins in BALF increased after high VT
ventilation from baseline in WT and Tpl2−/−mice (p < 0.001 vs. corresponding controls).
Yet, BALF proteins concentration was lower in Tpl2−/−than in WT mice after high VT
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Figure 2 Lung mechanics. Inspiratory capacity, defined as the volume (in ml/kg) to inflate the lungs to an
airway pressure of 25 cmH2O, expressed as percentage (%) of control, of wild-type (WT, white boxes), and
Tpl2-deficient mice (Tpl2−/−, gray boxes) subjected only to sample collection (control, n = 8 per group),
mechanical ventilation with normal tidal volume (VT) for 240 min (n = 7 to 9 per group), or high VT for
210 min (n = 8 to 9 per group), and WT mice subjected to 210 min of high VT ventilation treated with a
Tpl2 inhibitor, either prior (Tpl2inh pre, n = 5) or after initiation of high VT ventilation (Tpl2inh post, n = 5).
Wild-type mice subjected to high VT ventilation had lower inspiratory capacity compared to control WT
mice, as well as compared to similarly ventilated Tpl2−/−mice, and WT mice treated with the Tpl2 inhibitor,
*p < 0.01. Data are presented in box plots, where boxes represent 25th to 75th percentile; line represent
median and whisker represent min and max, in all figures.
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mice of both genotypes, but more severe in WT than in Tpl2−/−mice. BALF concentration
of IL-6 increased from control, more in WT than in Tpl2−/−mice, while the concentration
of MIP-2 in BALF increased only in WT mice and not in Tpl2−/−mice (Figure 5A,B). In
the histological examination, lungs from WT mice subjected to high VT ventilation
presented severe injury with the presence of mixed inflammatory infiltrates (neutrophils
and alveolar macrophages) in the interstitial and alveolar spaces, edema, and thickening
of the alveolar walls, and a lung injury score of 0.7. Lungs from Tpl2−/−mice subjected toWT                Tpl2-/-
High VT















Figure 3 Oxygenation. Arterial blood gas PaO2 from wild-type (WT, white boxes), and Tpl2-deficient mice
(Tpl2−/−, gray boxes) subjected to mechanical ventilation with normal tidal volume (VT) for 240 min, or high
VT for 210 min (n = 6 to 8 per group). PaO2 was lower in WT mice subjected to high VT than in similarly
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Figure 4 BALF protein. Bronchoalveolar lavage fluid (BALF) concentration of protein from wild-type (WT, white
boxes), and Tpl2-deficient mice (Tpl2−/−, gray boxes) subjected only to sample collection (control, n= 7 to 8 per
group), mechanical ventilation with normal tidal volume (VT) for 240 min (n= 6 to 8 per group), or high VT for
210 min (n= 7 to 9 per group), and WT mice subjected to 210 min of high VT ventilation treated with a Tpl2
inhibitor, either prior (Tpl2inh pre, n = 5) or after initiation of high VT ventilation (Tpl2inh post, n = 5). BALF
proteins' concentration was higher in WT and Tpl2−/−mice subjected to high VT ventilation, than in control WT
and Tpl2−/−mice, respectively, *p < 0.001. BALF proteins' concentration was higher in WT mice subjected to high
VT ventilation than in similarly ventilated Tpl2−/−mice, and WT mice treated with the Tpl2 inhibitor, #p < 0.01.
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injury score of 0.33 (Figure 6).Pharmacologic inhibition of Tpl2 protects from high VT ventilation-induced lung injury
The observation that Tpl2 deficiency is protective in our VILI model prompted us to
examine the potential therapeutic effect of pharmacologic inhibition of Tpl2 in high
VT-induced lung injury. First, we examined if pretreatment with Tpl2 inhibitor would
ameliorate VILI in WT mice. When WT mice were subjected to high VT ventilation, no
differences were observed between untreated mice and mice receiving an i.p. injection of
DMSO in normal saline (vehicle) in any of the parameters evaluated (data not shown),
and therefore, untreated mice were used as controls. Pretreatment with the Tpl2 inhibitor
was effective in preventing high VT-induced decrease in lung compliance (Figure 2).
Additionally, high VT-induced increase in the concentrations of protein, IL-6 and
MIP-2, observed in ventilated, untreated WT mice, was less in mice pretreated with
the Tpl2 inhibitor (Figures 4 and 5).
Although pretreatment was effective, such therapeutic approach is rarely feasible in clin-
ical practice. We, therefore, tested the effects of pharmacological Tpl2 inhibition when the
inhibitor was administered 30 min after the initiation of high VT ventilation. We found
that posttreatment with the Tpl2 inhibitor was also effective in ameliorating indices of
VILI. Lung compliance and concentrations of protein and IL-6 in BALF were similar be-
tween WT subjected to high VT ventilation and treated with the Tpl2 inhibitor either be-
fore or after initiation of high VT, and always lower than in untreated mice (Figures 2, 3, 4,
and 5). Although BALF concentration of MIP-2 was similar in mice treated with the Tpl2
inhibitor before or after high VT, only the pretreated group had significantly lower MIP-2
than the untreated group (Figure 5B).
Figure 5 Bronchoalveolar lavage fluid (BALF) concentration of (A) IL-6 and (B) MIP-2, from wild-type
(WT, white boxes), and Tpl2-deficient mice (Tpl2−/−, gray boxes) subjected only to sample collection
(control, n=5-8), mechanical ventilation with normal tidal volume for 240 min, or high tidal volume
for 210 min (n=5-7), and WT mice subjected to 210 min of high tidal volume ventilation treated
with a Tpl2 inhibitor, either prior (Tpl2inh pre, n=5), or after initiation of high VT ventilation
(Tpl2inh post, n=5). BALF IL-6 was lower in genotype-matched control mice than in ventilated mice, *p<0.05.
High tidal volume-induced increase in BALF IL-6 was greater in WT untreated mice, than in Tpl2−/− mice, and WT
mice treated with the Tpl2 inhibitor, *p<0.05. BALF MIP-2 concentration was higher in WT mice ventilated with
high VT than in WT control mice *p<0.001. BALF MIP-2 concentration was also higher in WT mice ventilated with
high VT than in similarly ventilated Tpl2−/− mice, and WT mice pre-treated with the Tpl2 inhibitor, *p<0.001.
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of Tpl2−/−mice and WT mice treated with the Tpl2 inhibitor
It is known that ERK1/2 activation contributes to the inflammatory response induced by
high VT ventilation, and that Tpl2 is an essential regulator of ERK1/2 activation. We
therefore examined ventilation-induced activation of ERK1/2 in alveolar macrophages and
total lungs homogenates from WT and Tpl2−/−mice. BALF cells from control, non-
Figure 6 Histology. Representative photographs of hematoxylin-eosin-stained lung sections, ×200 magnification,
from control wild-type and Tpl2-deficent mice and from wild-type and Tpl2-deficient mice subjected to high tidal
volume ventilation for 210 min (n= 4 per group) and calculated lung injury score. Mechanical ventilation with
high VT-induced lung injury that was more severe in WT than in Tpl2−/−mice *p< 0.01.
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of >85% alveolar macrophages (data not shown). Mechanical ventilation with high VT
but not normal VT increased ERK1/2 phoshorylation in alveolar macrophages of WT
mice (Figure 7). This increase in levels of phospho-ERK1/2 after high VT ventilation
was not observed in alveolar macrophages from Tpl2−/−mice and in those from WT
mice treated with the Tpl2 inhibitor. Levels of phospho-ERK1/2 were similar in lung
homogenates from WT and Tpl2−/−mice ventilated on high VT.Discussion
The inflammatory response and barrier dysfunction that characterize acute lung injury can
be exacerbated by mechanical ventilation, and, apart from low tidal volume ventilation, no
effective treatment is available yet. Identifying the intracellular signaling molecules involved
in VILI is thus important for designing novel therapeutic approaches. In the present study
we show that inhibition of Tpl2, a MAP3K kinase, is protective in a mouse model of VILI.
Indices of high-permeability pulmonary edema and lung inflammation induced by injurious
ventilation were lower in Tpl2-deficient mice than in WT ones. More importantly, this
protective effect was reproduced using pharmacologic inhibition of Tpl2 in WT mice.
It is well established that injurious ventilation induces high-permeability pulmonary
edema and inflammation. Studies in ARDS patients have shown that even brief periods
of injurious ventilation increase BALF inflammatory mediators [36]. In mouse models,
high tidal volume ventilation induces lung injury characterized by pulmonary edema
with increased concentrations of proteins and cytokines in BALF and inflammatory cell
infiltration and diffuse alveolar damage on histology, a picture similar to human ARDS
[1]. In this study, high VT ventilation-induced lung injury in WT mice, characterized
by deterioration in lung mechanics and oxygenation, increased concentration of
Figure 7 ERK1/2 phosphorylation. (A) The histograms are representative of p-ERK1/2 fluorescence intensity
of BALF CD11c positive cells (alveolar macrophages) from non-ventilated mice (n = 6), and from wild-type and
Tpl2-deficient mice exposed to either 60 min of normal tidal volume ventilation (n = 4 per group) or 30 min of
normal tidal volume ventilation followed by 30 min of high tidal volume ventilation (n = 4 per group), with or
without treatment with a Tpl2 inhibitor given 5 min prior to high tidal ventilation. BALF cells stained with
isotype control are also depicted. ERK1/2 phosphorylation, as indicated by mean fluorescent intensity (MFI), was
higher in WT mice subjected to high VT ventilation than in WT control mice and WT mice ventilated with
normal VT *p < 0.05. ERK1/2 phosphorylation was also higher in WT mice subjected to high VT ventilation than
in similarly ventilated Tpl2−/−mice and WT mice treated with the Tpl2 inhibitor *p < 0.05. (B) Representative
Western blot analysis for phosphorylated and total ERK1/2 of lung homogenates from non-ventilated mice
(n = 4 per group) and from WT and Tpl2−/−mice (n = 4 per group) exposed to 30 min of high tidal volume
ventilation. Mechanical ventilation was associated with increased ERK1/2 phosphorylation in lungs of both WT
and Tpl2−/−mice compared to genotype-matched control mice, *p < 0.05.
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deficiency was associated with less lung injury upon high VT ventilation. Specifically,
Tpl2-deficient mice showed no deterioration of lung mechanics and oxygenation, less
injury on histology, and lower levels of BALF proteins and cytokines than WT mice,
suggesting a protective role of Tpl2 inhibition in VILI.
The ERK1/2 pathway is a highly conserved signaling pathway involved in fundamental
cellular processes such as growth, differentiation, and survival. ERK1/2 is activated by a
wide variety of receptors including G protein-coupled receptors (GPCR), tyrosine kinase
receptors, TLRs, ion channels, and others [9,10]. Studies have shown that ERK1/2 is also
involved in mechanotransduction [1], and that ERK1/2 activation by mechanical stretch
contributes to the inflammatory response induced by injurious ventilation [4,15].
Tpl2 is an essential regulator of ERK1/2 activation, mediating signals initiated by cytokine or
Toll-like receptors to induce pro-inflammatory cytokine production [22,28]. In disease models,
Tpl2−/−mice were initially found to be resistant to LPS/D-galactosamine-induced endotoxin
shock [28]. Recent studies showed that Tpl2 deficiency was associated with reduced adipose tis-
sue inflammation in diet-induced obesity, and reduced acetaminophen-induced liver injury
[37,38]. In an experimental colitis model, pharmacologic as well as genetic inhibition of Tpl2
was found effective in reducing bowel inflammation [32]. Yet, the role of Tpl2 in inflammatory
lung diseases has not been investigated. Involvement of Tpl2 in lung inflammation has been
only indirectly demonstrated, since Tpl2 was found up-regulated in a proteome analysis of lung
tissues from rats exposed to cigarette smoke [39], and mice lacking Tpl2 had reduced lung in-
flammation in a model of acute pancreatitis [31]. This study showed that Tpl2 is involved in
barrier dysfunction and inflammation triggered by injurious ventilation, as inhibition of Tpl2
ameliorated lung inflammation and high-permeability pulmonary edema.
The pathway consistently shown to be impaired in the absence or inhibition of Tpl2 is the
ERK1/2 pathway [25,30-32,37]. Also in this study, high tidal volume-induced ERK1/2 activa-
tion was lower in alveolar macrophages from Tpl2−/−mice and from WT mice treated with
the Tpl2 inhibitor than from WT untreated mice. The observation that ERK1/2 activation
was similar in lung homogenates of WTand Tpl2−/−mice could be explained by the presence
of other ERK1/2 activating signals, not mediated by Tpl2, such as TGFβ or other growth fac-
tors. The possible inhibition of other kinases was not examined and cannot be ruled out.
An important finding of this study is that pharmacologic inhibition of Tpl2, and not only
genetic, was effective in ameliorating VILI. Systemic administration of a Tpl2 inhibitor pro-
tected from VILI, both when given as pretreatment and when given after initiation of injuri-
ous ventilation. A time point well after establishing high VT (30 min) was chosen as
posttreatment, reasoning that ERK1/2 activation occurs sooner, even within 5 min after high
stretch [14,15], and that a deterioration of lung injury resulting in high airway pressures
would be recognized by a clinician within 30 min and prompt therapeutic interventions. WT
mice receiving the Tpl2 inhibitor after being on high VT ventilation for 30 min had similar
lung mechanics, and BALF protein, IL-6 and MIP-2 concentrations as Tpl2−/−mice at the
end of the experiment, and lower than untreated, ventilated on high VT, WT mice. The only
observed difference was that the delayed treatment with the Tpl2 inhibitor was not able to
prevent the increase in BALF concentration of MIP2 induced by injurious ventilation. These
findings suggest that the protective effect of Tpl2 inhibition is quite well maintained when
the inhibitor is administered after an increase in airway pressure is observed, as it would hap-
pen in clinical practice.
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activation by inflammatory stimuli with a consequent reduction in side effects. Thus, in-
hibition of Tpl2 will not affect activation of ERK1/2 by other agonists, like growth factors,
which has been proven protective in several diseases, such as myocardial and cerebral
ischemia-reperfusion injury [40,41]. Small molecule inhibitors designed to suppress Tpl2
were able to inhibit pro-inflammatory cytokine production from LPS-treated human pri-
mary macrophages [42], supporting the therapeutic potential of Tpl2 inhibition. Addition-
ally, inhibition of Tpl2 has been a promising target for inflammatory diseases including
inflammatory bowel disease, rheumatoid arthritis and liver disease [42-44], and Tpl2 in-
hibitors are among the ones to be tested in clinical trials [18].
Of course the potential adverse effects of Tpl2 inhibition have been evaluated neither in
clinical practice nor under experimental conditions. Although Tpl2−/−mice appear to be
prone to chemically induced carcinogenesis in several animal models [22], they do not de-
velop spontaneous cancers, and the clinical importance of Tpl2-deficiency-mediated car-
cinogenesis in acute inflammatory conditions, such as VILI is probably small; as such
treatments would be given for only brief periods of time. Data on toxicity of Tpl2 inhibi-
tors are lacking, but an inhibitor of MEK1/2 (mitogen-activated protein kinase kinase), a
kinase that is upstream of ERK1/2 in the Raf-MEK-ERK pathway, has been investigated in
phase I and phase II clinical trials in patients with advanced malignancies and proved to
have a good safety profile [45-48]. A more important concern of Tpl2 inhibition is the po-
tential immune suppression. Indeed, Tpl2 ablation ameliorated macrophages response to
LPS [28,49], increased susceptibility of mice to Listeria monocytogenes infection [50], and
decreased clearance of Toxoplasma gondii [51]. It is possible that Tpl2 inhibition could ad-
versely affect critically ill patients with ongoing infection. This is a common limitation of
all anti-inflammatory therapeutic interventions, such as corticosteroids in ALI-VILI.
In this study, we use our established model of aseptic, ‘one-hit’ VILI [33], to clarify the
role of Tpl2. This ‘one-hit’ model is widely used in studies to investigate the pathogenesis
of VILI. Using this model, we were able to confirm that inhibition of Tpl2 ameliorates
indices of high-permeability pulmonary edema and inflammation induced by injurious
ventilation. Nonetheless, this ‘one-hit’ model has inherent limitations. Specifically, a very
high, not clinically relevant tidal volume has to be used. We and others have shown
[33,52,53] that only such high volume can result in distortion of lung units required to
induce VILI in healthy mice. Yet, it is now clear that in patients with ARDS some alveoli
are exposed to such high distending pressures [54]. Additionally, to compensate for the
hemodynamic effects of high intrathoracic pressures, mice receive fluid loading, that may
contribute to the development of pulmonary edema. As all groups of ventilated mice re-
ceived the same amount of fluids, but only the group of WT mice ventilated on high tidal
volume developed significant edema, it is reasonable to assume that fluid loading may
only exacerbate the high tidal volume-induced alteration in alveolar permeability.
Conclusion
In conclusion, Tpl2 contributes to the pathogenesis of high-permeability pulmonary edema
and inflammation induced by high tidal volume ventilation, as genetic deficiency of Tpl2
appears to be protective in this model of murine VILI. Additionally, pharmacologic inhib-
ition of Tpl2 is effective in ameliorating indices of VILI, even when given after establishing
injurious ventilation, suggesting a potential therapeutic role for Tpl2 inhibitors in VILI.
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